![Lloyd Paul Aiello](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Lloyd Paul Aiello
Società | Posizione | Inizio | Fine |
---|---|---|---|
KalVista Pharmaceuticals Ltd.
![]() KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Fondatore | 01/01/2011 | - |
Storia della carriera di Lloyd Paul Aiello
Precedenti posizioni note di Lloyd Paul Aiello
Società | Posizione | Inizio | Fine |
---|---|---|---|
KALVISTA PHARMACEUTICALS, INC. | Fondatore | 26/03/2004 | - |
Statistiche
Distribuzione geografica
Regno Unito | 2 |
Stati Uniti | 2 |
Posizioni
Founder | 2 |
Settori
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
KALVISTA PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 1 |
---|---|
KalVista Pharmaceuticals Ltd.
![]() KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Lloyd Paul Aiello
- Esperienza